Clear Search

Showing 1 result for “Chakravorty M”.

May 2022

Efficacy and Safety of Obinutuzumab in Systemic Lupus Erythematosus Patients with Secondary Non-response to Rituximab

Rheumatology 2022;00:1–5 DOI.org/10.1093/rheumatology/keac150

Arnold, et al. present the first case series reporting the efficacy and safety of obinutuzumab in patients with treatment refractory SLE. The results indicate that, for this group of patients with limited treatment approaches, obinutuzumab could be a potential option.

more…